Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) Debt to Equity (2016 - 2023)

vTv Therapeutics' Debt to Equity history spans 10 years, with the latest figure at -$0.05 for Q1 2023.

  • For Q1 2023, Debt to Equity rose 49.51% year-over-year to -$0.05; the TTM value through Mar 2023 reached -$0.05, up 49.51%, while the annual FY2022 figure was -$0.06, 50.85% up from the prior year.
  • Debt to Equity for Q1 2023 was -$0.05 at vTv Therapeutics, up from -$0.06 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.04 in Q4 2020 and bottomed at -$0.13 in Q4 2021.
  • The 5-year median for Debt to Equity is -$0.06 (2022), against an average of -$0.07.
  • The largest annual shift saw Debt to Equity plummeted 1459.67% in 2019 before it skyrocketed 50.85% in 2022.
  • A 5-year view of Debt to Equity shows it stood at -$0.05 in 2019, then soared by 32.45% to -$0.04 in 2020, then tumbled by 261.5% to -$0.13 in 2021, then surged by 50.85% to -$0.06 in 2022, then grew by 24.57% to -$0.05 in 2023.
  • Per Business Quant, the three most recent readings for VTVT's Debt to Equity are -$0.05 (Q1 2023), -$0.06 (Q4 2022), and -$0.09 (Q3 2022).